The present disclosure describes genetically modified host cells expressing or overexpressing one or more genes of an L-serine pathway, or an operon comprising such one or more genes, wherein the genes or operon are operably linked to a constitutive promoter having a nucleotide sequence which is at least 70 %, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, such as at least 99%, such as 100% identical to the constitutive promoter comprised in anyone of SEQ ID NO: 1 to 16.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
The present invention generally relates to the use of hydroxycinnamic acid or derivatives thereof, such as zosteric acid in a cosmetic or therapeutic setting. The present invention further relates to compositions comprising hydroxycinnamic acid or derivatives thereof.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 8/36 - Acides carboxyliquesLeurs sels ou anhydrides
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
A61Q 19/00 - Préparations pour les soins de la peau
A61Q 19/08 - Préparations contre le vieillissement
A61Q 5/00 - Préparations pour les soins des cheveux
A61K 8/368 - Acides carboxyliquesLeurs sels ou anhydrides dans lesquels le groupe carboxyle est directement lié aux atomes de carbone du cycle aromatique
4.
A LOW DOSE FORMULATION OF L-SERINE FOR LIVER HEALTH AND FATTY LIVER DISEASES
The present invention relates to a low dose formulation of L-serine for liver health and fatty liver diseases. More particularly, the present invention provides a formulation of L-serine for which the daily dose is between 2 and 15 g per person per day. The claimed formulations are efficacious and useful for fatty liver disease patients and individuals at risk of developing a fatty liver disease including individuals with elevated liver fat levels. Furthermore, the present invention provides novel efficient methods of use of such formulations.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
The present invention relates to a genetically engineered host cell producing a metabolite from 3- phosphoglycerate through a metabolic pathway, comprising one or more genetic modifications preventing or reducing or alleviating a negative impact on production of the metabolite from intracellular accumulation of NADH and/or hydroxy glutarate (HGA), produced by one or more pathway enzymes.
The present invention generally relates to the agricultural industry, and specifically to the protection of crops, seeds and fruits against fungal and/or oomycetes pests. The present invention provides the use of hydroxycinnamic acid or a derivative thereof for protection of crops, seeds or fruits against at least one fungal and/or oomycetes pest, wherein a composition comprising hydroxycinnamic acid or a derivative thereof is applied to the surface of said crops, seeds or fruits by spraying or by immersion into said composition.
A01N 31/16 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques de l'oxygène ou du soufre l'atome d'oxygène ou de soufre étant lié directement à un système cyclique aromatique avec plusieurs atomes d'oxygène ou de soufre liés directement au même système cyclique aromatique
A01N 37/02 - Acides carboxyliques saturés ou leurs thio-analoguesLeurs dérivés
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Fermentation extract; Fermentation extracts for industrial purposes; Sulfates; Flavonoids [phenolic compounds] for industrial purposes; Phenolic resins; Bacterial substances for scientific use; Bacterial substances for industrial use; Biochemical precursors for scientific purposes; Chemical polymers; Polymers for use in the analysis of biochemicals; Chemical and organic compositions for use in the manufacture of food and beverages; Chemical substances, chemical materials and chemical preparations, and natural elements; Acids; Organic acids for industrial use; Aromatics [chemicals]. Pharmaceuticals and natural remedies; Medical and veterinary preparations and articles. Research and development in the field of microorganisms and cells; Biochemical engineering services; Research and development services; Biochemical research and development; Pharmaceutical research and development; Scientific research and development; Research and development in the field of biotechnology; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of bacteriology; Science and technology services; Natural science services; Medical and pharmacological research services; Engineering services.
8.
PRODUCTION OF CYSTEINE OR CYSTINE FROM SERINE IN FERMENTATION MEDIUM
The present disclosure describes a method for producing cysteine and/or cystine comprising a) providing a fermentation medium comprising serine from of a genetically engineered host cell producing said serine; b) providing one or more sources of sulfur; c) providing one or more pyridoxal 5-phosphate (PLP)-dependent enzymes capable of converting serine into cysteine and/or cystine in the presence of the source of sulfur; d) contacting the serine in the fermentation medium with the pyridoxal 5-phosphate (PLP)- dependent enzyme in the presence of PLP and the source of sulfur under conditions allowing the serine to be converted into cysteine and/or cystine; and optionally e) recovering and/or isolating the cysteine and/or cystine.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Amino acids for industrial purposes; Amino acids for scientific purposes; Fermentation extract; Fermentation extracts for industrial purposes; Sulfates; Flavonoids for industrial purposes [phenolic compounds]; Phenolic resins; Bacterial substances for scientific use; Bacterial substances for industrial use; Biochemical precursors for scientific purposes; Chemical polymers; Polymers for use in the analysis of biochemicals; Chemical and organic compositions for use in the manufacture of food and beverages; Chemical substances, chemical materials and chemical preparations, and natural elements; Acids; Organic acids for industrial use; Aromatics [chemicals]; all the aforementioned being genetically engineered raw materials produced by a genetically engineered microbe; none of the aforementioned being for in vitro diagnostics or immunoassays. Amino acids for medical purposes; Amino acids for veterinary purposes; Amino acids for medical or veterinary purposes; Pharmaceuticals and natural remedies; Medical and veterinary preparations and articles; none of the aforementioned being finished preparations to be used for in vitro diagnostics or immunoassays; none of the aforementioned being for in vitro diagnostics or immunoassays. Research and development in the field of microorganisms and cells; Biochemical engineering services; Research and development services; Biochemical research and development; Pharmaceutical research and development; Scientific research and development; Research and development in the field of biotechnology; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of bacteriology; Science and technology services; Natural science services; Medical and pharmacological research services; Engineering services; none of the aforementioned being research on in vitro diagnostics and immunoassays.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Amino acids for industrial purposes; Amino acids for scientific purposes; Fermentation extract; Fermentation extracts for industrial purposes; Sulfates; Flavonoids for industrial purposes [phenolic compounds]; Phenolic resins; Bacterial substances for scientific use; Bacterial substances for industrial use; Biochemical precursors for scientific purposes; Chemical polymers; Polymers for use in the analysis of biochemicals; Chemical and organic compositions for use in the manufacture of food and beverages; Chemical substances, chemical materials and chemical preparations, and natural elements; Acids; Organic acids for industrial use; Aromatics [chemicals]; all the aforementioned being genetically engineered raw materials produced by a genetically engineered microbe; none of the aforementioned being for in vitro diagnostics or immunoassays. Amino acids for medical purposes; Amino acids for veterinary purposes; Amino acids for medical or veterinary purposes; Pharmaceuticals and natural remedies; Medical and veterinary preparations and articles; none of the aforementioned being finished preparations to be used for in vitro diagnostics or immunoassays; none of the aforementioned being for in vitro diagnostics or immunoassays. Research and development in the field of microorganisms and cells; Biochemical engineering services; Research and development services; Biochemical research and development; Pharmaceutical research and development; Scientific research and development; Research and development in the field of biotechnology; Research and development for the pharmaceutical industry; Consultancy relating to pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of bacteriology; Science and technology services; Natural science services; Medical and pharmacological research services; Engineering services; none of the aforementioned being research on in vitro diagnostics and immunoassays.
11.
Biological processes for the production of aryl sulfates
The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using polypeptides or recombinant cells comprising said polypeptides. More particularly, the present invention pertains to polypeptides having aryl sulfotransferase activity, recombinant host cells expressing same and processes for the production of aryl sulfates employing these polypeptides or recombinant host cells.
The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using recombinant host cells. More particularly, the present invention pertains to recombinant host cells comprising (e.g., expressing) a polypeptide having aryl sulfotransferase activity, wherein said recombinant host cells have been modified to have an increased uptake of sulfate compared to identical host cells that does not carry said modification. Further provided are processes for the production of aryl sulfates, such as zosteric acid, employing such recombinant host cells.
The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
The present invention generally relates to the field of biotechnology as it applies to the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity. More particularly, the present invention pertains to polypeptides having tyrosine ammonia lyase activity and high substrate specificity towards tyrosine, which makes them particularly suitable in the production of p-coumaric acid and other hydroxycinnamic acids. The present invention thus provides processes for the production of p-coumaric acid and other hydroxycinnamic acids employing these polypeptides as well as recombinant host cells expressing same.
The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using polypeptides or recombinant cells comprising said polypeptides. More particularly, the present invention pertains to polypeptides having aryl sulfotransferase activity, recombinant host cells expressing same and processes for the production of aryl sulfates employing these polypeptides or recombinant host cells.
The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using recombinant host cells. More particularly, the present invention pertains to recombinant host cells comprising (e.g., expressing) a polypeptide having aryl sulfotransferase activity, wherein said recombinant host cells have been modified to have an increased uptake of sulfate compared to identical host cells that does not carry said modification. Further provided are processes for the production of aryl sulfates, such as zosteric acid, employing such recombinant host cells.
The present invention generally relates to the microbiological industry, and specifically to the production of L-serine using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.
C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
The present invention relates to the production of hydrolyzates from a lignocellulose-containing material, and to fermentation of the hydrolyzates. More specifically, the present invention relates to the detoxification of phenolic inhibitors and toxins formed during the processing of lignocellulose-containing material by enzymatically sulfating the phenolic inhibitors and toxins using aryl sulfotranseferases.
C12P 7/10 - Éthanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
20.
Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
The present invention generally relates to the field of biotechnology as it applies to the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity. More particularly, the present invention pertains to polypeptides having tyrosine ammonia lyase activity and high substrate specificity towards tyrosine, which makes them particularly suitable in the production of p-coumaric acid and other hydroxycinnamic acids. The present invention thus provides processes for the production of p-coumaric acid and other hydroxycinnamic acids employing these polypeptides as well as recombinant host cells expressing same.
